Abstract:Objective: Mutations in driver genes contribute to the development and progression of lung adenocarcinoma (LUAD). However, in the dynamic evolutionary process from adenocarcinoma in situ (AIS) to minimally invasive adenocarcinoma (MIA) and eventually to invasive adenocarcinoma (IAC), the role of driver genes is currently unclear. This study aimed to analyse the role of driver gene status in the progression of LUAD from preneoplasia to IAC.Methods: Patients with LUAD who underwent surgery in our centre from March 2015 to December 2019 were retrospectively analysed, and LUAD patients with tumour sizes ≤3.0 cm and pN0 were included in the final analysis. The mutation status of common driver genes, including EGFR, ALK and ROS1, was detected. According to the pathological characteristics, the patients were divided into three stages: AIS, MIA and IAC. We analysed the distribution of driver gene mutation frequencies across three stages of LUAD. In addition, we performed univariate and multivariate analyses of IAC patients to screen for relevant variables (driver genes and clinicopathological features) affecting their prognosis.Results: Ultimately, 759 patients with LUAD were enrolled, including 135, 130, and 494 cases of AIS, MIA, and IAC, respectively. EGFR mutations were identified in 359 (61.8%) patients, and with the transition from AIS to MIA, the frequency of EGFR mutations increased from 33.3% to 50.8%, P=0.004, whereas the frequency of EGFR mutations was comparable for MIA and IAC (50.8% vs. 50.2%, P=0.922). Moreover, ALK and ROS1 gene fusions were identified in 17 cases (2.2%) and 2 cases (3.0‰) respectively. For AIS, neither ALK gene nor ROS1 gene fusions were observed. When the tumour progressed to MIA, the ALK fusion frequency was 2.3% (3/130), which was basically consistent with the ALK fusion frequency of 2.8% in IAC, P=0.143. For IAC, fusions of ROS1 fell into this category. In addition, we found that 40 patients (5.3%) developed metastasis/recurrence, and 14 patients (1.8%) died of cancer-specific related diseases. Notably, for AIS, there were no recurrences and no deaths, and for MIA, only 1 patient died with LUAD. Finally, survival analysis was performed in patients with IAC, and EGFR-mutant patients showed better DFS than EGFR-wild-type patients (P=0.036). Conversely, patients with ALK fusions showed worse DFS than those with ALK wild-type (P=0.004), and the same results were found in OS analysis.Conclusions: The accumulation of EGFR driver gene mutation frequencies mediates the progression of LUAD from AIS to MIA. When the tumour progresses to IAC, multivariate analysis based on driver gene status can be used as a pivotal prognostic factor.Funding Information: This study was funded by the Discipline Innovation Development Plan Project of Tangdu Hospital (2021LCYJ005), National Natural Science Foundation of China (82002421), and Special Fund for Elite Talents of Shaanxi Provincial People's Hospital(2021JY-20).Declaration of Interests: We declare that we have no conflicts of interest.Ethics Approval Statement: This study was approved by the Ethics Committee of Fourth Military Medical University Affiliated Tangdu Hospital (K202107-19), and all recruited patients signed an informed consent form.

Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

The Genomic Landscape of Young and Old Lung Cancer Patients Highlights Age-Dependent Mutation Frequencies and Clinical Actionability in Young Patients

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Targeted Next-Generation Sequencing of 491 Lung Cancers in Clinical Practice: Implications for Future Detection Strategy and Targeted Therapy

Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening

Investigating the Genomic Alteration Improved the Clinical Outcome of Aged Patients with Lung Carcinoma

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Concurrent Oncogene Mutation Profile in Chinese Patients with Stage Ib Lung Adenocarcinoma.

Analysis of gene mutation status and prognosis in lung cancer patients younger than 35 years old:a retrospective study

Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using Csmart and Prognosis Analysis

Dynamic Contribution of EGFR Mutation Status in Lung Adenocarcinoma from in Situ to Invasive Adenocarcinoma: A High-Volume Retrospective Study